Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease

DOI: 10.1371/journal.pone.0172916

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text